Results 131 to 140 of about 735,075 (277)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Report results: Impact of whole‐body resistance exercise timing on mitigating hyperglycaemia‐induced vascular dysfunction in healthy adults

Experimental Physiology
Postprandial hyperglycaemia is characterized by elevated blood glucose levels following a meal and is associated with impaired vascular endothelial function. Regular exercise has been shown to preserve and improve vascular endothelial function.
Laura K. Smith, Lauren Roach, Courtney R. Chang, Tannia Cyriac, Kate Oetsch, Evelyn B. Parr, Monique E. Francois   +6 more
doaj   +1 more source

THE HOME MEAL REPLACEMENT OPPORTUNITY: A MARKETING PERSPECTIVE [PDF]

Many food retailers perceive home meal replacements (HMR) or meal solutions as major opportunities for sales growth. These fully- or partially-prepared foods appear to solve growing consumer needs: lack of time, lack of skill, and lack of desire to ...
Larson, Ronald B.
core  

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

Association between Meal Timing and Multidimensional Sleep Health

Background: Optimal sleep health is crucial for well-being, with poor sleep health linked to chronic diseases and reduced quality of life. Interest in chrono-nutrition has uncovered potential ties between meal timing and sleep health.
Kim, Namhyun
core  

Metabolite and hormone rhythms : the effect of obesity type two diabetes and meal timing. [PDF]

, 2017
Daily rhythms are an important aspect of our physiology. A central clock in the hypothalamus tracks light-dark cycle and coordinates the ubiquitous peripheral clocks.
Isherwood, Cheryl M.
core  

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source

Re‐evaluating variability of circulating miR‐122 in healthy volunteers: Implications for biomarker qualification in drug‐induced liver injury

British Journal of Clinical Pharmacology, EarlyView.
Drug‐induced liver injury (DILI) remains a major challenge in clinical practice and drug development, and reliable biomarkers are still needed. MicroRNA‐122 (miR‐122) has shown promise, but reported inter‐individual variability in healthy populations has raised concerns about its clinical utility.
Irum Javid, Giusy Russomanno, Anthony Evans, Guruprasad P. Aithal, Shiva S. Forootan, Warren E. Glaab, Matthias Hackl, Joely Irlam, Kseniya Khamina‐Kotisch, Samantha Korver, Gerd A. Kullak‐Ublick, Sophia L. Samodelov, Christopher E. Goldring   +12 more
wiley   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

British Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu, Amina Haggag, Laurie Butcher, Haihui Liu, Wen Chen, Xuefeng Sun, Aruni Jha, Hongtao Yu, Anis Khan, Victoria E. R. Parker, Christer Tannergren, Xiaoliang Pan, Jianfeng Xu, Jingye Zhou   +13 more
wiley   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang, Yoonjin Kim, Daye Jung, Jae Min Cho, Joo‐Youn Cho, SeungHwan Lee   +5 more
wiley   +1 more source